Ascendis Pharma A/S of Denmark has issued 6.9 million shares in the United States at $18 per share, generating net proceeds of $111.5 million. In early trading on 3 February 2015 the shares traded at $19.08 on the Nasdaq, representing a 6.0% premium.
